Haruspex AI Analysis

Johnson & Johnson JNJ

Analyzed for: swing

76/100

Bullish — Johnson & Johnson (JNJ) shows strong momentum with an overall score of 76/100. Strength in Institutional Ownership Inte...

Momentum: +12 strong

Key Takeaways

Biggest Positive Factor

Institutional Ownership Intelligence

Score 68/100 · Change +0

Biggest Risk

Competitive Intelligence

Score 66/100 · Change +0

Why now

Johnson & Johnson (JNJ) shows strong momentum with an overall score of 76/100. Strength in Institutional Ownership Intelligence (68) is complemented by Competitive Intelligence (66). Position sizing should reflect the current bullish outlook.

Top Factor

Institutional Ownership Intelligence

68/100 · +0

Analysis Reliability

High

Full confidence framework unlocks after signup.

Why Now

  • Top support: Institutional Ownership Intelligence is 68/100 (Institutional Ownership Intelligence currently adds bullish pressure for JNJ. JNJ has 77.0% institutional ownership across 5,767 institutions . Net institutional buying detected. Watch strong institutional accumulation may support price to confirm or weaken this signal.).
  • Main risk: Competitive Intelligence is 66/100 (Competitive Intelligence currently adds bullish pressure for JNJ. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide operates in the Drug Manufacturers - General industry, ranking #1 by market cap among 3 peers. Profitability exceeds industry peers. Watch follow-through in competitive intelligence signals to confirm or weaken this signal.).
  • Johnson & Johnson (JNJ) shows strong momentum with an overall score of 76/100. Strength in Institutional Ownership Intelligence (68) is complemented by Competitive Intelligence (66). Position sizing should reflect the current bullish outlook.

Top Factors

  • Institutional Ownership Intelligence 68/100 · +0
  • Competitive Intelligence 66/100 · +0

Analysis Snapshot

Overall Outlook: Bullish

Strongest Area: Institutional Ownership Intelligence (68/100)

Main Concern: Competitive Intelligence (66/100)

Price Movement: Low — Pretty stable

Drivers: 5,767 institutional holders | Buy/sell ratio: 42.30 (net +2,212,224.395 shares) | 77.0% institutional ownership

Risks: Competitive advantages: market leader, best margins, fastest growth | Ranked #1 of 3 by market cap | Profit margin +10.5% vs industry avg

Timeline Outlook: Johnson & Johnson (JNJ) shows strong momentum with an overall score of 76/100. Strength in Institutional Ownership Intelligence (68) is complemented by Competitive Intelligence (66). Position sizing should reflect the current bullish outlook.

What to watch:

  • Strong institutional accumulation may support price
  • follow-through in competitive intelligence signals

Competitive Intelligence

Score: 66/100

Confidence: High confidence

low impact

Competitive Intelligence currently adds bullish pressure for JNJ. Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide operates in the Drug Manufacturers - General industry, ranking #1 by market cap among 3 peers. Profitability exceeds industry peers. Watch follow-through in competitive intelligence signals to confirm or weaken this signal.

Key drivers:

  • Competitive advantages: market leader, best margins, fastest growth
  • Ranked #1 of 3 by market cap
  • Profit margin +10.5% vs industry avg

Signal: Above Average (change: +0)

Institutional Ownership Intelligence

Score: 68/100

Confidence: High confidence

low impact

Institutional Ownership Intelligence currently adds bullish pressure for JNJ. JNJ has 77.0% institutional ownership across 5,767 institutions . Net institutional buying detected. Watch strong institutional accumulation may support price to confirm or weaken this signal.

Key drivers:

  • 5,767 institutional holders
  • Buy/sell ratio: 42.30 (net +2,212,224.395 shares)
  • 77.0% institutional ownership

Signal: Above Average (change: +0)

Recent News

Company Profile

Development, manufacturing, and sale of healthcare products

Profile Refresh: Feb 17, 2026

Business model
Development, manufacturing, and sale of healthcare products
Customer type
Patients, providers, and consumers
Industry group
Healthcare
Subindustry
Pharmaceuticals

Operational Exposure

China exposure
Moderate: Increasing tensions between the U.S. and China may impact business. inferred from risk factors.
Supply chain dependency
High: Subject to supply chain constraints due to changing regulations and potential manufacturing delays. inferred from risk factors.

Revenue Mix

Risk Factors Preview

Item 1A. Risk factors for additional description of cybersecurity risks and potential related impacts on the Company. Governance - management’s responsibility The Company takes a risk-based approach to cybersecurity and has implemented cybersecurity controls designed to address cybersecurity threats and risks. The Chief Information Officer (CIO), who is a member of the Company’s Executive Committee, and the Chief Information Security Officer (CISO) are responsible for assessing and managing cybersecurity risks, including security incident detection, response, and recovery. The Company’s CISO, in coordination with the CIO, is responsible for leading the Company’s cybersecurity program and management of cybersecurity risk. The current CISO has over twenty-five years...

Unlock the Full Analysis

Scores, signals and portfolio views for hundreds of stocks across 20+ dimensions — each one dated before the move and measured against the S&P 500 afterwards.

Create Free Account

Get the weekly AI market brief

Top-scored stocks, biggest movers, and what the board flagged — one email, every Monday. No spam, unsubscribe anytime.